Neonatal epidermolysis bullosa simplex: a mechanobullous skin fragility disease
DOI:
https://doi.org/10.18203/2349-3291.ijcp20260828Keywords:
Epidermolysis bullosa, Newborn, Inherited skin disorder, Skin blistering, Skin fragility, GenodermatosisAbstract
Epidermolysis bullosa (EB) is a group of hereditary skin blistering disorders characterised by skin fragility and mechanically induced blistering. We present a case of a full-term female neonate with widespread, fragile blisters and erosions at birth, prompting early suspicion of EB. Rapid dermatological evaluation and immunofluorescence antigen mapping confirmed EB simplex (EBS), allowing prompt intervention. Early parental counselling plays a crucial role in ensuring confidence in home care. After six weeks, the mother managed feeding and wound care independently. This case highlights the importance of recognising neonatal skin fragility early, facilitating timely diagnosis and intervention to minimise complications and improve long-term outcomes in infants with EB.
References
Sawamura D, Nakano H, Matsuzaki Y. Overview of epidermolysis bullosa. J Dermatol. 2010;37:214-9.
Fine JD, Eady RA, Bauer EA. The classification of inherited epidermolysis bullosa (EB): report of the third international consensus meeting on diagnosis and classification of EB. J Am Acad Dermatol. 2008;58:931-50.
McGrath JA. Recently identified forms of epidermolysis bullosa. Ann Dermatol. 2015;27:658‐66.
Takeichi T, Nanda A, Liu L, Salam A, Campbell P, Fong K, et al. Impact of next generation sequencing on diagnostics in a genetic skin disease clinic. Exp Dermatol. 2013;22:825‐31.
Has C, Fischer J. Inherited epidermolysis bullosa: New diagnostics and new clinical phenotypes. Exp Dermatol. Epub. 2018;28(10):1146-52.
Yuen WY, Duipmans JC, Molenbuur B, Herpertz I, Mandema JM, Jonkman MF. Long-term follow-up of patients with Herlitz-type junctional epidermolysis bullosa. Br J Dermatol. 2012;167(2):374-82.
Gonzalez ME. Evaluation and treatment of the newborn with epidermolysis bullosa. Semin Perinatol. 2013;37(1):32-39.
Wally V, Hovnanian A, Ly J, Buckova H, Brunner V, Lettner T, et al. Diacerein orphan drug development for epidermolysis bullosa simplex: A phase 2/3 randomized, placebo-controlled, double-blind clinical trial. J Am Acad Dermatol. 2018;78:892-901.
Kumar V, Behr M, Kiritsi D, Scheffschick A, Grahnert A, Homberg M, et al. Keratin-dependent TSLP expression suggests a link between skin blistering and atopic disease. J Allergy Clin Immunol. 2016;138:1461-4.
Castela E, Tulic MK, Rozières A, Bourrat E, Nicolas JF, Kanitakis J, et al. Epidermolysis bullosa simplex generalized severe induces a Th17 response and is improved by apremilast treatment. Br J Dermatol. 2019;180(2):357-64.
AlKhawajah, NM, AlKhawajah MM, Aljomah NA, Alabduljabbar AA, Alkeraye S. Epidermolysis bullosa simplex clearance after nasopharyngeal carcinoma treatment. JAAD Case Rep. 2021;12:60-3.